These thrombus prolongs in the heart and falls off, causing cerebral infarction.
Thrombosis is usually considered to be a "blood clot" formed in blood vessels, which prevents the flow of blood. In patients with coronary heart disease, thrombosis can lead to complete blockage of the coronary artery that feeds the heart, leading to myocardial infarction. In addition to the blood vessels, in fact, there will be thrombosis in the heart, bringing the risk of stroke! Cheng Cai, Deputy Director of Cardiovascular Surgery, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, introduced that "These thrombus are most likely to grow in the left atrium (the protruding part of the left atrium in the right anterior direction). The left atrium and the left atrium are a reservoir of the heart, and the blood in the atrium will drain into the ventricle. When there is thrombus in the ear, it will be latent in the heart for a long time. With the beating of the heart, the thrombus may fall off at any time. Once it falls off, most of the thrombus will quickly run to the brain and induce cerebral infarction. The remaining 20% will run to other parts of the body, causing embolism, causing great harm. There are four valves in our hearts, which are equivalent to valves that control blood flow in our hearts.
Our hearts have four valves. Many diseases can lead to valvular disease. The most common valvular disease in our country is rheumatic heart disease. This kind of disease can cause severe mitral stenosis, which can lead to unobstructed blood flow. If not treated in time, there will be an arrhythmia called atrial fibrillation. Mitral stenosis and atrial fibrillation are prone to thrombosis in uneven areas such as the left atrial appendage. Only Cheng cautioned that patients with valvular disease and atrial fibrillation should not neglect treatment because their symptoms are tolerable. They should take anticoagulants and be operated on to avoid the occurrence and loss of cardiac thrombosis.
Looking for chemical products? Let suppliers reach out to you!
2026-06-28
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
European Medicines Agency: AstraZeneca vaccine may have potential link with thrombosis
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
Pfizer Warns Germany Over Drug-Pricing Policy
-
India Raises Cancer Drug Price Caps by 50%
-
Roche Keeps German Diagnostics Investment
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Iran Conflict Leaves a Long Shadow on Drug Supply
-
AstraZeneca India Eyes ₹3,400 Crore Bengaluru Sale
-
Amazon Turns Lilly’s Weight-Loss Pill Into a Retail Logistics Play
Recommend Reading
-
Sun Pharma’s Organon Bid Would Redraw Indian Pharma M&A
-
McKinsey Pays to Close a Purdue Liability Chapter
-
Minoxidil Safety Under Global Review as Infant Exposure Risks Surface
-
Substandard Drug Findings Expose Deep Structural Gaps in Medicine Quality Control
-
Obesity Drugs Become Pharma’s Most Powerful Growth Engine
-
China’s Titanium Dioxide Giant Makes a Move: LB Group Acquires UK Venator Assets
-
Acetonitrile: Properties, Uses, and Safety
-
LBB Specialties to Distribute Imerys' Mineral Ingredients in North America
-
The 94th API China
-
Premium Global Chemical Sourcing Requests (25-27May, 2026)